HC Wainwright & Co. Reiterates Neutral on Galectin Therapeuticsto Neutral

Benzinga Newsdesk Apr 2, 2025 1 year ago

NewsReiterationAnalyst Ratings

HC Wainwright & Co. analyst Ed Arce reiterates Galectin Therapeutics (NASDAQ:GALT) from Neutral to Neutral.